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ThegrowingunderstandingoftheuseofbiomarkersinAlzheimer’sdisease(AD)mayenablephysicianstomakemoreaccurateand
timely diagnoses. Florbetaben, a beta-amyloid tracer used with positron emission tomography (PET), is one of these diagnostic
biomarkers. This analysis was undertaken to explore the potential value of ﬂorbetaben PET in the diagnosis of AD among patients
with suspected dementia and to identify key data that are needed to further substantiate its value. A discrete event simulation
was developed to conduct exploratory analyses from both US payer and societal perspectives. The model simulates the lifetime
course of disease progression for individuals, evaluating the impact of their patient management from initial diagnostic work-up
toﬁnaldiagnosis.ModelinputswereobtainedfromspeciﬁcanalysesofalargelongitudinaldatasetfromtheNewEnglandVeterans
Healthcare System and supplemented with data from public data sources and assumptions. The analyses indicate that ﬂorbetaben
PET has the potential to improve patient outcomes and reduce costs under certain scenarios. Key data on the use of ﬂorbetaben
PET, such as its inﬂuence on time to conﬁrmation of ﬁnal diagnosis, treatment uptake, and treatment persistency, are unavailable
and would be required to conﬁrm its value.
1.Introduction
Alzheimer’s disease (AD) is a fatal and progressive neurode-
generative disorder that aﬀects millions of people worldwide
[1]. It is currently the sixth leading cause of death in the
United States (US), with about 80,000 deaths associated with
AD in 2009 [2], and has imposed substantial burden on
patients, their caregivers, medical care payers, and society
as a whole [3]. With the baby-boomer generation aging,
the economic and humanistic burdens caused by AD are
expected to grow considerably if eﬀective interventions
cannot be discovered in time.
There is still no cure for AD. Cholinesterase inhibitors
and memantine are the only major pharmacological treat-
ments currently available to slow the symptoms associated
with disease progression. Clinical studies have demonstrated
modest beneﬁts of these treatments in improving the symp-
toms related to AD [4, 5]. Prior studies have also indicated
that identifying patients with AD and treating them at an
early stage could result in cost savings and health beneﬁts
compared with treating them at a later stage due to the
absence of early assessment [6, 7]. Current diagnostic tools
in the early diagnosis of AD, however, are imprecise and
detect the disease only based on the symptoms. Misdiagnosis2 International Journal of Alzheimer’s Disease
anddelayeddiagnosis ofAD, therefore,have been commonly
reported [8–10].
The current diagnosis of AD is mainly based on clinical
grounds according to the guidelines developed jointly by the
National Institute of Neurological and Communicative Dis-
orders and Stroke and the Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA). Although sen-
sitive for AD, the NINCDS-ADRDA guidelines have poor
speciﬁcity [11], which could lead to a great number of false
positive cases and, consequently, unnecessary treatment. The
growingknowledgeintheuseofbiomarkersofADpathology
is very likely to provide physicians with new tools to not only
improve the diﬀerential diagnosis of AD but also identify
AD at an earlier stage and even before symptoms occur. The
International Working Group for New Research Criteria for
the Diagnosis of AD has recently revised the deﬁnition of
AD to include both the predementia (or prodromal AD),
referring to the early symptomatic phase of AD that is
still not suﬃciently severe to aﬀect instrumental activities
of daily living, and dementia (or AD dementia) phases. It
has also recommended that the diagnosis of AD relies on
a dual clinicobiological process that entails the evidence
of both speciﬁc cognitive impairments and biomarkers
of AD pathology that can include retention of amyloid
tracers on positron emission tomography (PET); cerebral
spinal ﬂuid (CSF) beta-amyloid, total tau, and phospho-tau;
medialt emporallobeatr o p h y(MT A)onmagneticr esonanc e
imaging (MRI); and/or temporal/parietal hypometabolism
on ﬂuorodeoxyglucose (FDG-) PET [12].
Florbetaben, a beta-amyloid tracer, is one of the novel
diagnostic tools that can be used to detect neuropatho-
logical changes related to AD in vivo. It binds to beta-
amyloid plaques and can be detected using a PET scan. The
predictive values of ﬂorbetaben PET are currently under a
phase III assessment, but preliminary phase II data have
shown promising results in discriminating AD from other
dementias and healthy controls [13–15]. The implications of
this diagnostic tool in detection, diagnosis, and treatment of
AD in actual clinical practice could be substantial once it is
approved for use. However, due to increasing health resource
constraints, the widespread use of ﬂorbetaben PET in the
future clinical practice would depend not only on its clinical
value but also its economic impact. Thus, the purposes of
this study were to develop an early exploratory economic
model assessing the potential clinical and economic value of
ﬂorbetaben PET in the diagnosis of AD and to identify key
value drivers as well as data gaps, which will direct the future
research to support the future economic assessment of this
technology. The design of this model and the ﬁndings from
this assessment could also be very useful to guide further
research assessing the cost eﬀectiveness of other biomarkers,
in the diagnosis of AD.
2.MaterialsandMethods
The model explores the potential clinical and economic con-
sequences of using ﬂorbetaben PET in the usual diagnostic
process for the diagnosis of AD from both the US payer
and societal perspectives. Usual diagnostic care refers to
a period of diagnostic work-up during which speciﬁc
diagnostic tests are performed over a series of medical visits
to obtain the needed information for conﬁrmation of a
speciﬁc type of dementia diagnosis. Diﬀerent combinations
of diagnostic tests and assessments, along with other tests
of pathophysiological (e.g., amyloid tracers and total tau)
and/or topographical makers (e.g., FDG and MTA), received
by patients during the diagnostic work-up period, could
have diﬀerent predictive values in terms of diﬀerentiating
AD from other forms of dementia; there are numerous
possible combinations of the tests and assessments that can
be received by patients during the work-up period. Thus, for
the purpose of simplicity and availability of the existing data
to inform the predictive values of each speciﬁc combination
of tests received by patients, the possible combinations of
the diagnostic tests in this model were categorized into
the following algorithms: clinical guidelines alone (e.g.,
NINCDS-ADRDA) and clinical guidelines plus one of the
following tests: (1) MRI of MTA, (2) computerized tomogra-
phy (CT) of MTA, (3) FDG-PET, (4) single photon emission
computer tomography (SPECT), (5) CSF of beta-amyloid,
total tau, phospho-tau, or beta-amyloid plus total tau, and
(6) PET of ﬂorbetaben beta-amyloid tracers. Patients in
the nonﬂorbetaben group (or called usual diagnostic care
group hereafter) can be proportionally assigned to any of
these diagnostic algorithms, except for the clinical guidelines
plus ﬂorbetaben PET, to obtain an aggregate measure of
sensitivity and speciﬁcity associated with the diagnostic
algorithms assigned.
This model was implemented as an individual patient
simulation using discrete event simulation (DES) [24]. This
modelling technique was selected mainly due to its capability
to track events experienced by patients over the course
of simulation and to use them, along with other relevant
patient and disease characteristics, to predict the course of
disease progression over time. This feature, along with other
advantages, has led to increasing use of DES in assessing
the cost eﬀectiveness of treatments in patients with AD
[7, 25, 26].
2.1. Model Concept. Figure 1 shows the simpliﬁed schematic
representation of the model concept. The target model
population includes patients with some form of dementia
whopresenttodoctoroﬃcesfortheﬁrsttime,andthosewith
cognitive problems due to other illnesses, such as depression
or schizophrenia, were not considered in this analysis.
Patients could make their initial doctor visit in either the
predementia or dementia phase of the disease. The latter can
be further divided into several levels of severity based on the
Mini-Mental State Examination (MMSE) scores. Patients in
the dementia phase are assigned an underlying pathological
cause of dementia, which can be one of the following types
of dementia: AD, mixed AD, vascular dementia (VaD), Lewy
body dementia (LBD), frontotemporal dementia (FTD),
and mixed non-AD. Those in the predementia phase are
also assigned an underlying cause of either prodromal AD
or nonprodromal AD, which could be any of the non-
AD dementia listed above if the patient progresses to theInternational Journal of Alzheimer’s Disease 3
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Figure 1: Schematic representation of the model concept.
dementia phase. Relevant patient and disease characteristics,
such as age, gender, race, location of care, baseline severity,
and comorbidities, are also assigned to each patient at the
beginning of the simulation conditional on their underlying
cause.
Each patient in the model undergoes a period of diag-
nostic work-up following their initial doctor visit. At the
end of the diagnostic work-up period, all the predementia
patients are assumed to be correctly conﬁrmed with a
predementiadiagnosis, andthoseassignedtotheﬂorbetaben
grouparegivenaPETscan,withdementiatreatment,suchas
cholinesterase inhibitors and memantine, initiated for those
with a positive AD result. For those assigned to the usual
diagnostic care group, all or some proportion of the patients
mayreceivedementiatreatmentwithoutscreeningaftertheir
predementia diagnosis is conﬁrmed.
Forthedementiapatients,allpatientsareconﬁrmedwith
a speciﬁc type of dementia at the end of diagnostic work-
up, but the correctness of the diagnosis is dependent on
the predictive values of the diagnostic algorithm assigned to
the patient. Dementia treatment is initiated to all dementia
patients in the ﬂorbetaben group with a positive AD result,
but not to those with a negative result at the time of
diagnosisconﬁrmation.Forthoseintheusualdiagnosticcare
group, some dementia patients also have a chance to receive
dementia treatment at the time of conﬁrmation, depending
on the result of diagnosis. Patients with a positive AD result
but not treated at the time of conﬁrmation could receive
dementia treatment at a later time.
Dementia treatment may delay progression to the de-
mentia phase for patients with predementia. When a patient
develops dementia, treatment may slow progression to a
more severe stage of the disease, as well as need for
institutional care, but the eﬀect of treatment could be
negatively impacted by misdiagnosis and nonpersistence
with treatment. Disease progression in this model was
modelled through the interrelated changes in 3 domains
over time: cognition, using MMSE scale; behaviour, using
the Neuropsychiatric Inventory (NPI) scale; function, using
both the activities of daily living (ADL) and instrumental
activities of daily living (IADL) scales. In this model, it is
assumed that only those with prodromal AD, AD, or mixed
AD as the underlying cause of dementia would beneﬁt from
the treatment with cholinesterase inhibitors or memantine.
Treatmentinitiatedinpatientswithnon-ADwouldonlyhave
an impact on treatment costs.
Disease progression continues during the diagnostic
work-up period. Shortening the time required to correctly
conﬁrm a diagnosis would allow appropriate treatments to
be initiated at an earlier stage of the disease and thus could4 International Journal of Alzheimer’s Disease
result in greater health beneﬁts at lower costs. Use of ﬂor-
betaben PET in this model could directly inﬂuence 4 major
areas: (1) time required to conﬁrm a diagnosis, (2) accuracy
of diagnosis, (3) proportion of patients receiving appropriate
dementia treatments at conﬁrmation, and (4) persistence
with treatment. Each of these impacts is associated with
speciﬁc clinical and economic consequences. Finally, this
model allows those who are misdiagnosed to be correctly
rediagnosed at a later time and receive treatment. Death can
occur at any point in time, and is dependent on patient
age, gender, underlying cause of dementia, and stage of the
disease(i.e.,predementiaanddementiaphases).Asimpliﬁed
model ﬂow diagram showing how patients are simulated is
displayed and explained in Appendix A.
2.2. Data Sources. The primary data source used to populate
this model was based on the administrative databases from
New England Veterans Healthcare System (VISN 1) from
January 1, 2002 through December 31, 2009 (ﬁscal years
2002–2009). Speciﬁc analyses from the VA VISN 1 data
were performed to obtain the majority of the model inputs.
Detailed information on the VA VISN 1 data can be seen
in Appendix B. Model inputs which could not be obtained
from the VA VISN 1 data were supplemented with data from
literature, public databases, and assumptions.
2.2.1. Model Settings. A reference-case analysis was per-
formed based on 1,000 simulated patients per group per run
for a total of 10 replications. The model time horizon for the
reference-case analysis was lifetime, which is commonly used
fortheassessmentinthistherapeuticarea.Costsandbeneﬁts
were discounted at 3% per annum [27]. Additionally, disease
severity was divided into ﬁve levels based on the ranges
of MMSE scores previously used by the United Kingdom
National Institute for Health and Clinical Excellence [28].
2.2.2. Patient and Disease Characteristics at Baseline. Data
used to create the model population in the simulation were
mainly obtained from the VA VISN 1 data, supplemented
with data from literature. Among the patients with a
conﬁrmed diagnosis, 68% of them were conﬁrmed with a
dementia diagnosis and 32% with a predementia diagnosis.
For those with a dementia diagnosis, 67% had a conﬁrmed
diagnosis of AD or mixed AD, 28% had a VaD, and
the remaining 5% had other dementia diagnoses, such as
LBD, FTD, and mixed non-AD. For those diagnoses with
predementia, 65% were assumed to have prodromal AD,
which was estimated based on a chart review of a subset of
thesepatients. Themeanageatinitial diagnosis wasabout78
years for patients with predementia and 82 years for patients
with dementia. Data used to assign gender to the model
populations (about 30% male) were obtained from literature
[29–31] rather than from the VA VISN 1 data as almost all
patients in the study cohort were male.
BaselineMMSEscoreswereobtainedfromachartreview
of a subset (n = 229) of the VA VISN 1 study cohort,
indicating that more than 60% and 80% of the AD and non-
AD patients, respectively, had the MMSE scores above 20 at
initial diagnosis. As the NPI, ADL, and IADL scores were not
available from the VA VISN 1 data, assumptions were made
to assign the baseline scores for these measures consistent
with the distribution of severity level based on the baseline
MMSE scores.
2.2.3. Diagnostic Algorithms and Corresponding Predictive
Values. The proportions of patients in the usual diagnostic
care group undergoing a speciﬁc diagnostic algorithm were
obtained from the VA VISN 1 data (Table 1). Table 1 also
shows sensitivity and speciﬁcity by severity of the disease for
each diagnostic algorithm. Data, except for ﬂorbetaben PET,
were from a recent meta-analysis conducted by Bloudek and
colleagues [11]. The sensitivity and speciﬁcity of ﬂorbetaben
PET were supplied by the manufacturer of ﬂorbetaben
tracers based on its internal analyses of preliminary phase
II data as well as published data from other amyloid tracers
[13–15].
2.2.4. Time to Conﬁrmation of Diagnosis. The amount of
time taken to conﬁrm a speciﬁc type of dementia diagnosis
from the initial oﬃce visit under usual diagnostic care was
predicted using parametric equations derived from the VA
VISN 1 data. Table 2 shows the equation for each diagnosis.
Predictors with a positive coeﬃcient indicate a longer time
to conﬁrmation of diagnosis as the values of the predictors
increase and vice versa. The VA VISN 1 data show that the
averagetimetodiagnosisconﬁrmationwasabout5.1months
for AD or mixed AD, 6.1 months for VaD, 5.7 months for
other non-AD, and 5.5 months for predementia diagnosis.
In the reference-case analysis, use of a ﬂorbetaben PET was
assumed to lead to a 50% reduction in time to diagnosis
conﬁrmation under usual diagnostic care. As the evidence to
support this still does not exist, extensive sensitivity analyses
were used to assess the impact of these assumptions on
predicted outcomes.
2.2.5. Dementia Treatment. Dementia medications can be
initiated at either the time of diagnosis conﬁrmation or a
later time for those patients in the usual diagnostic care
group (Table 3). The majority of the patients were treated
with donepezil based on the VA VISN 1 data. For patients
in the usual diagnostic care group who were not treated at
diagnosis conﬁrmation, their time to treatment initiation
was predicted using the parametric equations derived from
the VA VISN 1 data (Table 2), indicating a median time of 28
months to treatment initiation for the dementia cohort and
42 months for the predementia cohort.
Patients on any dementia treatment may discontinue
over time. Table 2 shows the parametric equations used
to predict the time to discontinuation based on the VA
VISN 1 data, indicating a median time of 36 months to
treatment discontinuation for patients with dementia and 42
months for patients with predementia. The latter included
the duration of treatment during the dementia phase. In
the reference-case analysis, it was assumed that use of
ﬂorbetaben PET could reduce the risk of discontinuation by
50%. This assumption, also tested in the sensitivity analyses,International Journal of Alzheimer’s Disease 5
Table 1: Distribution of diagnostic algorithms and corresponding accuracy by severity (based on MMSE).
Diagnostic algorithm % Mild Moderate and severe
Usual care Florbetaben Sensitivity Speciﬁcity Sensitivity Speciﬁcity
Clinical guidelines only 73% 0% 87% 59% 77% 73%
Clinical guidelines with
MRI of MTA 8% 0% 82% 66% 85% 80%
CT of MTA 19% 0% 80% 87% 80% 87%
FDG-PET 0% 0% 91% 75% 91% 86%
SPECT 0% 0% 79% 81% 68% 86%
CSF Aβ1-42 0% 0% 72% 75% 74% 79%
CSF Aβ1-42 + Ttau 0% 0% 86% 64% 84% 72%
CSF Ttau 0% 0% 77% 73% 82% 71%
CSF Ptau 0% 0% 77% 73% 82% 78%
Florbetaben PET 0% 100% 90% 90% 90% 90%
MRI: magnetic resonance imaging; MTA: medial temporal lobe atrophy; CT: computer tomography; PET: positron emission tomography; FDG:
ﬂuorodeoxyglucose; SPECT: single photon emission computer tomography; CSF: cerebral spinal ﬂuid.
is based on the rationale that the improved accuracy of
ﬂorbetaben PET may increase physicians’ and patients’ level
of conﬁdence in the diagnosis and therefore encourage them
to persist longer with treatment.
In this model, dementia treatment can also be forced
to stop under some conditions speciﬁed by the users. In
the reference-case analysis, patients with dementia were
allowed to receive dementia treatment for lifetime as long as
their MMSE scores were greater than 10; patients with
predementiawereassumedtoreceivetreatmentfornolonger
than ﬁve years if the patient did not covert to the dementia
phase.
2.2.6. Disease Progression. Patients with predementia may
convert to the dementia phase at a later time. Data on
time to conversion, also from the VA VISN 1 data, were
ﬁtted to a Weibull function (Table 2). Based on the VA
VISN 1 data, the median time to conversion was about 35
months. In the reference-case analysis, it was assumed that
dementia treatment during the predementia phase would
reduce the risk of conversion by 50% among those patients
with prodromal AD, although the evidence to support such
clinical beneﬁts remains uncertain. This assumption was
madetoalsoassessthepotentialbeneﬁtsofusingﬂorbetaben
PET to screen predementia patients for treatment if a new
eﬀective treatment becomes available in the near future.
Treatment for those patients with nonprodromal AD would
have no clinical beneﬁt but would have a cost impact.
Disease progression for patients with AD or mixed AD
was modelled based on the interrelated changes in MMSE,
NPI, ADL, and IADL over time. Data used to simulate the
disease progression were based on the predictive equations
(Table 2) obtained from a study conducted by Getsios and
colleagues [25]. On the other hand, disease progression for
patients withnon-AD dementia wassimulatedonlybasedon
changesinMMSEovertimeduetolackofdataonNPI,ADL,
and IADL. The same equation from Getsios and colleagues
was used without any adjustment as few studies have shown
that patients with other non-AD dementia, except for FTD,
have similar rates of decline in cognition to those with AD
[32–35]. For patients with FTD, the annual rate of change in
MMSE scores was adjusted by −4.4 points [34].
2.2.7. Time to Institutional Care. Two Weibull equations
derived from the VA VISN 1 data were used to predict
the time to institutional care for dementia and predemen-
tia patients (Table 2). Age was the only predictor in the
equation for patients with predementia, indicating that the
older patients are more likely to need institutional care
than younger patients. On the other hand, predictors in
the equation for patients with dementia include type of
dementia diagnosis, time to conﬁrmed diagnosis, and use
of any dementia medication. Patients diagnosed with AD
were more likely to need institutional care than patients
diagnosed with other types of dementia; a longer time to
conﬁrmation of diagnosis was associated with a shorter time
to institutional care; the and use of any dementia medication
was associated with a longer time to institutional care.
2.2.8. Time to Death. Time to death was predicted using two
gender-speciﬁcGompertzfunctionsderivedfromtheUSLife
Tablebasedonpatientsage55yearsandabove(Table 2)[36].
These baseline risks were adjusted with hazard ratios of 1.48
for patients with predementia, 2.84 for patients with AD or
mixedAD,and2.69forpatientswithnon-ADdementia[37].
2.2.9. Costs and Resource Uses. Cost inputs and their
corresponding sources are shown in Table 4.C o s ti t e m s
considered in this model included costs of diagnostic work-
up, imaging and biomarker tests, dementia medications,
and medical and nonmedical care for predementia and
dementia, including caregiver time. All cost inputs used 2011
values. Detailed information on cost inputs can be viewed in
Appendix C.
2.2.10. Utilities. The model estimates utilities for both pa-
tients and their caregivers. Health utilities for patients with6 International Journal of Alzheimer’s Disease
Table 2: Equations for prediction of time to events and disease progression.
Equation Coeﬃcient and predictor SD/shape Distribution
Time to conﬁrmation of a diagnosis
AD or mixed AD 4.571 + 0.327Male + 0.252MixedAD − 0.353CKD 0.965 Lognormal
VaD 4.529 + 0.158Diabetes + 0.203Hypertension + 0.385Stroke 1.005 Lognormal
Other non-AD dementia 6.558 − 0.029Age + 1.554Stroke + 0.654LBD + 0.400FTD 0.896 Lognormal
Predementia 3.981 + 0.009Age − 0.243CKD − 0.179CVD 0.994 Lognormal
Time to treatment initiation if not
started at diagnosis
Dementia 7.149 − 0.022Age + 1.056VaD + 2.091Other non-AD + 0.004
(time, in days, to conﬁrmed diagnosis) 1.517 Lognormal
Predementia 18.781 − 0.150Age 3.996 Lognormal
Time to treatment discontinuation
Dementia 7.487 − 0.0008 (time to conﬁrmed diagnosis) 0.922 Weibull
Predementia 7.122 + 0.443 (conversion to dementia) 1.131 Weibull
Time to conversion to dementia Scale = 0.0212 0.952 Weibull
Rate of change in MMSEa 5.4663 − 0.4200PM1 − 0.0042PM2 + 0.1415PM3 −
0.079PrevRate + 0.07474Age + δi N/A N/A
Rate of change in NPIb
(5.74 − 0.64Treatment + 0.03Weeks − 0.59NPIbase− 0.59NPI
Weeks + 0.24NPIrecent− 1.74White − 3.82Black + 2.34PsyMed
+ 0.12MMSEbase− 0.22MMSErecent + δi) ∗ 1.44
N/A N/A
Rate of change in ADL
1.35 − 0.81Treatment + 0.06Weeks − 0.79ADLbase +
0.71IADLprevious + 0.12MMSEbase + 0.09Age + 0.81PsyMed −
3.05Black − 0.49MMSErecent + δi
N/A N/A
Rate of change in IADL
1.27 + 0.63Treatment + 0.17Weeks − 0.06Treatment ∗ Weeks
− 0.84IADLbase − 0.002IADLbase∗ Weeks + 0.84IADLprevious−
0.67Male + 0.20MMSEbase− 0.28MMSErecent− 0.16ADLbase +
0.18ADLrecent + δi
N/A N/A
Time to institutional care
Dementia
9.883 − 0.02Age + 0.295VaD + 1.154Other non-AD −
0.001Time to conﬁrmed diagnosis + 1.079Dementia treatment 0.933 Weibull
Predementia 11.469 − 0.028Age 1.373 Weibull
Time to death
Male Scale = −9.697 0.087 Gompertz
Female Scale = −10.787 0.097 Gompertz
Patient utility
0.408 + 0.010MMSE − 0.004NPI − 0.159Institutionalized +
0.051Living with Caregiver N/A N/A
Caregiver utility 0.90 − 0.003AgeCG +0 . 0 3M a l e CG + 0.001Male − 0.001NPI −
0.001ADL − 0.0004IADL − 0.01PsyMed N/A N/A
SD: standard deviation; AD: Alzheimer’s disease; VaD: vascular dementia; LBD: Lewy body dementia; LTD: frontotemporal dementia; CKD: chronic kidney
disease; CVD: cerebrovascular disease; MMSE: mini-mental state examination; NPI: neuropsychiatric inventory; ADL: activities of daily living; IADL:
instrumental activities of daily living, CG: caregiver.
aPMrepresentspatients’previousMMSEmeasurement,partitionedoverthescaleofMMSE.PrevRateisthepatients’lastknownrateofdecline.Agerepresents
patients’ age at baseline. δi represents a random intercept parameter.
bTreatment is dementia medication, Weeks represents weeks of followup in the simulation, NPIbase is the patient’s baseline NPI, and NPIrecent is the patient’s
last NPI. White and Black are dummy variables for race, PsyMed is a dummy variable for patients on psychiatric medications at baseline, MMSEbase represents
the patient’s MMSE at baseline, and MMSErecent represents the patient’s current MMSE.International Journal of Alzheimer’s Disease 7
Table 3: Model parameters for treatments.
Parameter
Dementia Predementia Data source
Usual care Florbetaben Usual care Florbetaben
% of patients receiving dementia medication at
diagnosis
N/A N/A 28% N/A VA VISN 1 and user speciﬁcation
If Dx = AD+ 77% 100% N/A 100%
If Dx = non-AD 67% 0% N/A 0%
Distribution of dementia medication Dx = AD+ Dx = Non-AD VA VISN 1
Donepezil 63% 66% 76%
Galantamine 25% 9% 6%
Rivastigmine 5% 4% 1%
Memantine 7% 21% 17%
Maximum dementia treatment duration
allowed, years
Life time 5 User speciﬁcation
Stopping dementia medication if MMSE score
is below 10
Yes N/A User speciﬁcation
AD: Alzheimer’s disease; Dx: dementia diagnosis; MMSE: mini-mental state examination; N/A: not applicable.
AD were estimated based on a published regression equation
shown in Table 2 [38]. Health utilities for patients with non-
AD were estimated by adjusting 0.006 lower compared to
their AD counterparts [39]. A utility weight of 0.82 was used
for patients with predementia [40]. Caregiver utilities were
predictedwithanequation(Table 2)fromareportbyGetsios
and colleagues [25].
3. Results
3.1. Reference-Case Analyses
3.1.1. At Baseline. Of the 1,000 simulated patients, 32% had
predementia and 68% dementia, replicating the underlying
input data. Of those patients with predementia, 65% had
prodromal AD as the underlying cause. Patients with prede-
mentia had a mean age of 78 years, and mean scores of 27.5
on the MMSE, 2.5 on the NPI, and 10.1 on both ADL and
IADL scales. On the other hand, for those with dementia,
67% had AD or mixed AD as the underlying cause, 28%
had VaD, and 5% had LBD, FTD, or other mixed no-AD
dementia with a mean age of 82 years and mean scores of
21.9 on the MMSE, 16.3 on the NPI, 29.7 on ADL, and 29.1
on IADL scales.
3.1.2.PredementiaCohort. Thereference-caseanalysisshows
that the average time to conﬁrmation of predementia
diagnosis was 4.64 months under usual diagnostic care,
which was slightly lower than the time indicated by the VA
VISN 1 data due to death and early conversion to dementia
during the diagnostic work-upperiod, and2.49months with
use of ﬂorbetaben PET.
Due to death and early conversion, only about 92%
(n = 295) of the predementia patients in the ﬂorbetaben
group received the scan. Of these, 62% had a positive result,
consisting of 58% true positive cases and 4% false positive
cases (i.e., patients had non-AD dementia, but misdiagnosed
ashavingAD),andthusreceiveddementiatreatment.Forthe
remaining 38% of patients with a negative result, including
31% true negative and 7% false negative cases (i.e., patients
had AD, but misdiagnosed as having non-AD dementia),
dementia treatment was not initiated. The ﬂorbetaben group
hadameanlifeexpectancyof0.10yearslongerthantheusual
diagnostic group (Table 5), which was due to the delay in
conversiontodementiainwhichtheriskofdeathwasgreater.
On average, patients in the ﬂorbetaben group had better
other clinical outcomes than patients in the usual diagnostic
groups in terms of time staying in predementia phase, time
to institutional care, time spent in severer stages of the
disease, and caregiver time (Table 5). These resulted in net
discounted cost savings of $12,374 per patient over lifetime
in direct medical care, $643 in caregiver time, and $13,018
in total cost. These savings were mainly due to reduction
in several cost areas, with the greatest savings coming from
reduced institutional care. Moreover, these clinical beneﬁts
also led to a net QALY gain (Table 5), making the use of
ﬂorbetaben PET a dominant strategy in identifying and
treating patients with prodromal AD under this reference-
case scenario.
3.1.3. Dementia Cohort. The reference-case results for the
dementia cohort are also shown in Table 5. The average time
to diagnosis conﬁrmation was about 5.08 months with the
usual diagnostic care group versus 2.66 months with the
ﬂorbetaben group. Due to death, about 91% of the patients
intheusualdiagnosticcaregroupand95%intheﬂorbetaben
groupcompletedthediagnosticwork-up.Morepatientswere
misdiagnosed in the usual diagnostic care group, with 12%8 International Journal of Alzheimer’s Disease
Table 4: Cost inputs.
Cost item Value Unit Data source
Diagnostic work-up
AD+ $5,120 Per year
VaD $5,885 Per year VA VISN 1 and [16–18]
Other non-AD $6,638 Per year
Predementia $6,187 Per year
Imaging and biomarker tests
MRI + MTA $437 Per test
CT + MTA $300 Per test
FDG-PET $1,042 Per test [16], manufacturer
SPECT $596 Per test
CSF $304 Per test
Florbetaben PET $2,300 Per test
Dementia medication
Donepezil $7.79 Per day
Galantamine $6.36 Per day [19]
Rivastigmine $6.11 Per day
Memantine $7.89 Per day
Medical care for predementia $5,548 Per year [20]
Medical care for AD+
Mild $8,315 Per year
Mildly moderate $12,806 Per year
Moderate $12,806 Per year [20]
Moderately severe $18,526 Per year
Severe $23,227 Per year
Nonmedical care for AD+
Mild $154 Per year
Mildly moderate $3,692 Per year
Moderate $12,166 Per year [20]
Moderately severe $14,209 Per year
Severe $23,355 Per year
% of additional cost of care for non-AD relative to AD
VaD 84%
[21]
Other non-AD 37%
Institutional care $373 Per day [22]
Caregiver time $7.25 Per hour [23]
Caregiver burden for predementia 2.10 Hours per day [20]
Caregiver burden for dementia
Mild 2.10 Hours per day
Mildly moderate 3.58 Hours per day
Moderate 3.58 Hours per day [20]
Moderately severe 3.76 Hours per day
Severe 5.10 Hours per day
AD: Alzheimer’s disease; VaD: vascular dementia; MRI: magnetic resonance imaging; MTA: medial temporal lobe atrophy; CT: computer tomography; PET:
positron emission tomography; FDG: ﬂuorodeoxyglucose; SPECT: single photon emission computer tomography; CSF: cerebral spinal ﬂuid.
false-negative and 11% false-positive cases versus 7% false-
negativeand3%false-positivecasesintheﬂorbetabengroup.
As expected, the average life expectancy for both groups was
the same. On average, patients in the ﬂorbetaben group had
better clinical outcomes than the usual care group (Table 5),
leading to net discounted cost savings of $11,086 per patient
over lifetime in direct medical care, $303 in caregiver time,
and $11,389 in total cost. The majority of the cost savings
resulted from reduction in costs associated with institutional
care. QALYs for patients and caregivers were greater with
the ﬂorbetaben group, but the diﬀerences were very small.
This, nevertheless, still indicated that use of ﬂorbetaben PETInternational Journal of Alzheimer’s Disease 9
Table 5: Reference-case results.
Outcome (per patient) Predementia cohort (n = 320) Dementia cohort (n = 680)
Usual care Florbetaben Net Usual care Florbetaben Net
Survival, years 6.84 6.94 0.10 4.57 4.57 0.00
Time to conﬁrmed diagnosis, months 4.64 2.49 −2.15 5.08 2.66 −2.42
Time in predementia, years 3.22 3.56 0.34 N/A N/A N/A
Time to institutional care, years 5.48 5.72 0.24 3.17 3.29 0.12
Time in severity, years
Mild 3.53 3.82 0.29 0.56 0.60 0.04
Mildly moderate 0.46 0.44 −0.02 0.77 0.78 0.01
Moderate 0.48 0.45 −0.03 0.71 0.71 0.00
Moderately severe 0.42 0.40 −0.01 0.57 0.56 −0.01
Severe 1.96 1.83 −0.13 1.96 1.92 −0.05
Caregiver time, years 0.92 0.91 −0.01 0.77 0.76 −0.01
Costs (discounted)
Total direct medical care $301,599 $289,225 −$12,374 $314,156 $303,070 −$11,086
Caregiver time $47,914 $47,271 −$643 $42,311 $42,008 −$303
Total $349,514 $336,496 −$13,018 $356,466 $345,077 −$11,389
QALYs (discounted)
Patients 3.53 3.68 0.15 1.75 1.78 0.03
Caregivers 4.29 4.41 0.12 2.59 2.60 0.01
Total 7.82 8.09 0.27 4.34 4.37 0.03
ICERs (discounted)
Patients Dominant Dominant
Caregivers Dominant Dominant
Total Dominant Dominant
QALYs: quality-adjusted life years; ICERs: incremental cost-eﬀectiveness ratios.
Note: inconsistency may occur due to rounding.
in usual diagnostic care was a dominant strategy in the
diagnosis of AD under this reference-case scenario.
3.2. Deterministic Sensitivity Analyses
3.2.1. Predementia Cohort. Figure 2 shows the top 15 model
parameters with the greatest impact on total net costs.
Given that the model results are very sensitive to variations
in percent of patients treated in the usual diagnostic care
group, treatment eﬀect, and percent reduction in time to
diagnosisconﬁrmationbyﬂorbetabenPET,scenarioanalyses
were conducted to understand the combined impact of the
last two parameters on total net QALYs and costs in a
scenario where all patients with a predementia diagnosis
in the usual diagnostic care group were treated without
screening. Figure 3 shows the results of the scenario analyses,
indicating that treating all predementia patients without
screening could be a dominant strategy as compared to using
ﬂorbetaben PET to screen patients with prodromal AD for
treatmentif thereis no reductionin the time toconﬁrmation
of dementia diagnosis with ﬂorbetaben PET. The cost eﬀec-
tiveness of ﬂorbetaben PET would become more favourable
if predementia treatment is less eﬀective under this scenario.
This is because more patients in the usual diagnostic care
group are treated than in the ﬂorbetaben group. Assuming
that a treatment could reduce the risk of conversion by 25%
to 50%, it would require at least a 40% reduction in time
to diagnosis conﬁrmation in order for the use of ﬂorbetaben
PETtobeadominantstrategyunderthisparticularscenario.
3.2.2. Dementia Cohort. The top 15 parameters inﬂuencing
the net cost based on the dementia patients were similar
to those observed in the predementia cohort, but the levels
of signiﬁcance for some model parameters were somewhat
diﬀerent (Figure 4). The dominance of ﬂorbetaben PET
could be altered if it had no impact on time to diagnosis
conﬁrmation.
3.3. Probabilistic Sensitivity Analyses. Detailed information
on how the probabilistic sensitivity analyses were performed
can be viewed in Appendix D. Figures 5 and 6 show the
incremental cost eﬀectiveness planes resulting from the
probabilistic sensitivity analyses based on 1,000 replications.
The cost eﬀectiveness of ﬂorbetaben PET in the diagnosis
of patients with prodromal AD is quite uncertain as the
incremental cost eﬀectiveness ratios (ICERs) scatter across 4
diﬀerent quadrants (Figure 5). Based on the results of 1,000
replications, use of ﬂorbetaben PET among the predementia
patients has net QALYs gained of 0.08, ranging from a worst
case of −0.67 to a best case of 1.29, and an average net total10 International Journal of Alzheimer’s Disease
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Figure 2: Results of univariate sensitivity analyses based on predementia cohort.
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Figure 3: Impact of percent reduction in time to diagnosis on net
cost and quality-adjusted life-years.
cost of −$3,059, ranging from −$101,109 to $93,610. Using
a willingness-to-pay threshold of $50,000 for one QALY,
ﬂorbetaben PET would be considered cost eﬀective in 58%
of the replications.
Unlike the results based on the predementia patients,
almost all the ICERs based on the dementia patients spread
in the fourth quadrant of the incremental cost eﬀectiveness
plane (Figure 6), indicating the dominance of ﬂorbetaben
PET over usual diagnostic care. Based on the results of 1,000
replications, use of ﬂorbetaben PET among patients with
dementiaisassociatedwithanaveragenetQALYgainof0.02,
ranging from 0.0006 to 0.09, and a net total cost of −$9,525,
ranging from −$44,210 to $1,117. With a willingness-to-pay
threshold of $50,000 for one QALY, ﬂorbetaben PET is cost
eﬀective in 98% of the replications.
4. Discussion
To our knowledge, this is the ﬁrst model to assess the cost
eﬀectiveness of a biomarker in the early diagnosis of AD
with DES to simulate the course of disease progression from
predementia to dementia phase and its clinical management
from initial diagnostic work-up to treatment initiation.
The greater detail underlying the DES framework allows
exploration of the potential value of biomarker use in the
early diagnosis of AD, identiﬁcation of major data gaps,
and assessment of the uncertainty in outcomes associated
with those gaps. As the model closely resembles the course
of disease and its management at individual patient level,
it inevitably requires richness of data to support the
simulation. To deal with the data issue, we undertook a
comprehensive analysis of longitudinal data from VA VISN
1 to characterize usual care pertaining to the diagnosis
and treatment of AD and other forms of dementia in the
US and to provide direct empirical estimates of various
aspects of usual care of the diseases. With the use of
advanced modelling technique, along with the support of
comprehensivedatafromtheVAVISN1,thismodelprovides
a better understanding of how patients would be aﬀectedInternational Journal of Alzheimer’s Disease 11
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Figure 4: Results of univariate sensitivity analyses based on dementia cohort.
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Figure 5: Incremental cost eﬀectiveness plane for predementia
cohort.
over time if a diagnostic biomarker like ﬂorbetaben PET
tracer is used and which model parameters would have
major inﬂuence on the model outcomes for speciﬁc patient
groups. However, it should be noted that the results from
the reference-case analysis are based on many important
assumptions. Solid evidence to support or refute these
assumptions is necessary before more conclusive estimates
can be produced.
The reference-case scenario indicates that use of ﬂor-
betaben PET in the diagnosis of AD results in both health
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Figure 6: Incremental cost eﬀectiveness plane for dementia cohort.
beneﬁts and cost savings. The probabilistic sensitivity analy-
sessuggestthatsuchmodeloutcomesarepositiveinthegreat
majority of cases when ﬂorbetaben PET is used in patients
with dementia but are subject to a greater uncertainty when
used in patients identiﬁed with predementia. The greater
uncertainty in the latter case is mainly due to lack of data
on several critical model parameters. The deterministic sen-
sitivity analyses indicate that improved accuracy of diagnosis
alone would not be adequate to yield suﬃcient clinical
beneﬁts and cost oﬀsets to justify the use of ﬂorbetaben PET
in the diagnosis of AD. Other clinical beneﬁts, especially if
it would shorten the time taken to conﬁrm a dementia or12 International Journal of Alzheimer’s Disease
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Figure 7: Model ﬂow.
predementia diagnosis, are needed to further support its cost
eﬀectiveness.
Thereasonsthereductionintimetoconﬁrmeddiagnosis
is so important to the cost eﬀectiveness of ﬂorbetaben PET
are not only that early diagnosis could allow appropriate
dementia treatment to be initiated at an earlier stage of
the disease, but also that reduction in time to diagnosis
conﬁrmation has a direct beneﬁcial impact on time to insti-
tutional care. The risk of needing institutional care would be
reduced by about 12% for every 100-day reduction in time
to diagnosis conﬁrmation, as indicated by the analyses of the
VA VISN 1 data. The causal relationship between them is still
unclear. It is possible that early conﬁrmation of diagnosis
would allow patients and their family members to plan
ahead and make needed adjustments to keep patients living
independentlyaslongaspossiblebeforetheyaresenttolong-
term-care facilities. Given that institutional care is costly, any
minor delay to institutional care would have a meaningful
impact on oﬀsetting the cost of the scan. Data from a survey
study, conducted alongside the ﬂorbetaben PET phase IIA
trial[41]seemtoalsosuggestthatuseofﬂorbetabenPETcan
reduce the time to diagnosis conﬁrmation. The survey shows
that directly visualizing and evaluating a patient’s amyloid
burden in vivo highly increases the conﬁdence of physicians
inmakingtheirﬁnaldiagnosis,suggestingthatphysiciansare
very likely to shorten the diagnostic work-up by eliminating
additional examinations and “watchful” waiting period
before suﬃcient symptoms are observed and consequently
initiate appropriate treatment at an earlier stage. This could
have a substantial positive impact on health and resource
utilization beneﬁts as there were approximately 72% and
23% of patients with predementia and AD diagnoses in the
VAVISN1studycohort,respectively,whodidnotreceiveany
dementia medication at conﬁrmation until a median time of
42and28monthsafterconﬁrmation.Useofﬂorbetabenmay
shorten the delay to receipt of appropriate care substantially
and result in better clinical and economic outcomes.
Three additional important ﬁndings from the present
analyses are worth mentioning as they may have important
implications for future economic assessment of the ﬂor-
betaben PET tracer in the early diagnosis of AD. First, a
large discrepancy on time to conﬁrmed diagnosis was found
from the VA VISN 1 data when diﬀerent approaches, that is,
analysis of administrative data versus chart review of a subset
of the study cohort, were used to quantify this duration. The
estimated duration based on the analyses of the VA VISN 1International Journal of Alzheimer’s Disease 13
datamaybettercapturethetimetakentoconﬁrmadementia
diagnosis fromthe initial oﬃce visit because a diagnosis code
wouldnormallyberecordedtorepresentthemaincomplaint
for a particular oﬃce visit. Yet, the estimated duration of
1.5 years based on the review of medical records should
be a good proxy for the time to conﬁrmation of diagnosis
from the early signs and symptoms of AD as these could
be recorded in the medical charts during the oﬃce visits for
other medical problems. The implication of this discrepancy
seemstoposeagreatopportunityforﬂorbetabenPETtracers
to identify patients with prodromal AD even at a much
earlier stage if clinicians know when to use them. This would
haveasubstantial,favourableimpactonthecosteﬀectiveness
of ﬂorbetaben PET tracers.
Second, our deterministic sensitivity analyses show that
youngerpatientswouldhaveagreatergaininnetcostsavings
and QALYs from the use of ﬂorbetaben PET. This is due
to a longer life expectancy in this population. In order to
treat patients with prodromal AD or AD dementia at a
younger age, screening general populations at younger ages
seems to be a reasonable strategy. Although screening the
generalpopulationforADisnotthefocusofthisassessment,
the signiﬁcant gain in economic and clinical beneﬁts in the
younger group from our analyses does suggest a promising
possibility to support such an application for ﬂorbetaben
PET tracers. This could also have valuable beneﬁts to some
of the patients who choose to know their disease propensity
as early as possible despite the absence of eﬀective treatments
during the preclinical or predementia phase as it allows
them to plan ahead with their life for personal and ﬁnancial
reasons [42, 43].
Third, as there is still no convincing evidence to support
that treatment with cholinesterase inhibitors would yield
any survival beneﬁt, this model assumes that survival
is independent of treatment eﬀect, consistent with the
assumption made in other published models [25, 26]. It is
nevertheless important to highlight that if treatment does
result in improved survival due to reduction in the rate
of disease progression, use of ﬂorbetaben PET would yield
more QALYs gained, but at the same time would result in
higher overall costs, especially for long-term care. As future
disease modifying treatments for AD may extend survival,
this may have an important impact on the economic value
of ﬂorbetaben PET and should be considered in future
economic assessment of this technology.
The present model has several major limitations. First,
because the current analyses are mainly based on the data
from the New England VA Healthcare System, the ﬁndings
from this analysis may not be generalizable to patients in
other regions of the VA Healthcare System, as well as in
other healthcare systems outside of the VA system. Second,
an external validation of this model to examine how well the
model can predict the results observed in other studies has
notyetbeenconductedduetolackofanappropriateexternal
data source. However, the results of key model components,
including disease progression during the dementia phase
and time to clinical events shown in Table 2, were validated
against the results from their respective data sources. A more
complete external validation should be conducted when
appropriate data source becomes available. Third, consistent
with many other modelling studies in this therapeutic area
[25, 26], continued treatment with dementia medication
after 1 year was assumed to have a maintenance function
only and no further treatment beneﬁts in terms of delaying
disease progression. Fourth, the model assumes that all
patients who present to their doctor for memory complaints
have some type of dementia. This may not be completely
true as memory complaints or cognitive problems could
be caused by other health problems, such as depression.
Inclusion of these patients who in fact have no dementia
may have some impact on the model results, depending on
the prevalence of these conditions. Finally, the model, for
the purpose of simplicity, assumed that all non-AD patients
with a negative result at the end of diagnostic work-up
would have their diagnosis correctly conﬁrmed. This might
have underestimated the beneﬁts of ﬂorbetaben PET as it
helps rule out AD as the underlying cause with a greater
degreeofcertaintycomparedtootherdiagnostictools,which
may consequently help identify the true cause for non-AD
dementia.
5. Conclusions
This economic model provides a comprehensive framework
to explore the potential clinical and economic value of
ﬂorbetaben PET in the early diagnosis of AD among patients
who present to their physicians’ oﬃce for the ﬁrst time due
to cognitive complaints, to identify key value drivers as well
as potential data gaps. Our exploratory analyses suggest that
ﬂorbetaben PET has the potential to be a valuable tool in the
diagnosis of AD as it would improve the health beneﬁts of
patients (with dementia as well as predementia) and their
caregivers at a lower cost under certain scenarios. While the
ﬁndings from the analyses to a large extent are supported by
the data from a large longitudinal database and published
literature, they rest also on many key assumptions and are
subject to great uncertainty. Data on how the technology
would impact clinical decision making and outcomes, such
as time to conﬁrmation of diagnosis, treatment uptake, and
treatment persistency, will be needed to further substantiate
its value.
Appendices
A. Model Flow
A simpliﬁed ﬂow diagram showing how patients are sim-
ulated in the model is displayed above. At the beginning
of the simulation, the model creates 1,000 patients with
diﬀerent types of dementia, based on the prevalence of
dementia for each type speciﬁed by the user, and assigns
patient and disease characteristics conditional on their
underlying cause. These characteristics include age, gender,
race, baseline scores for Mini-Mental State Examination
(MMSE), Neuropsychiatric Inventory (NPI), activities of
daily living (ADL), instrumental activities of daily living
(IADL), location of care (either home or institutional care),14 International Journal of Alzheimer’s Disease
use of antipsychotics, comorbidities (i.e., chronic kidney
disease, cardiovascular disease, diabetes, and hypertension),
and caregiver’s gender and age. These characteristics are
used to predict the rate of disease progression and other
model outcomes, such as time to death, time to institutional
care, time to conﬁrmation of diagnosis, costs of care, and
health utilities. After the assignments of baseline patient
characteristics and event times, each patient is cloned; one
clone is assigned to the usual diagnostic care group and the
other to the ﬂorbetaben group. The cloning step used in the
simulation resembles a perfect randomization where both
groups are comprised of exactly the same patients. For those
assigned to the ﬂorbetaben group, their time to conﬁrmation
of diagnosis is updated based on a percent reduction in time
to diagnosis speciﬁed by the user. Then, all patients are sent
to the “search next event” module, where the next event for
each patient is identiﬁed based on the event with the shortest
time to occur. There are a total of 10 events conceptualized
in this model, as shown in diagram above. After identifying
the next event for a patient, the model then fast-forwards its
clock to the next event time. Before the event is processed
for its related consequences, such as updates of patient
and treatment statuses and time to next event, all time-
dependent outcomes—including survival, quality-adjusted
life-years (QALYs), costs of care, caregiver time, time alive
at each stage of the disease, and time spent in institutional
care—are tallied and accumulated. After processing the
consequencesoftheevent,thepatientproceedstothe“search
next event” module again, and the same process is repeated
until the patient dies or the model time ends see Figure 7.
B.DatabaseAnalysis
The primary data source used to populate this model was
based on the administrative databases (clinical, laboratory,
and pharmacy databases) from New England Veterans
Healthcare System (VISN 1) from January 1, 2002 through
December 31, 2009 (ﬁscal years 2002–2009). The New Eng-
land region consists of eight Veterans Administration (VA)
Medical Centers and aﬃliated clinics providing inpatient
and outpatient medical care. The VISN 1 pharmacy ﬁles
were obtained from Information Resource Management,
Boston, MA. ICD-9-CM diagnoses and laboratory data were
captured by accessing the VA National Patient Care and
Decision Support Systems administrative databases (Patient
Treatment File and Outpatient Care File) located at the
Austin Automation Center, Austin, TX. All database analyses
were conducted at the Massachusetts Veterans Epidemiology
Research and Information Center (MAVERIC), VA Boston
Healthcare System, Boston, MA. The study was approved by
the Institutional Review Board of the VA Boston Healthcare
System.
Speciﬁc analyses from VISN 1 were performed to obtain
themajorityofthemodelinputs,includingthefollowing:(1)
prevalence of dementia for each type and baseline patients
and disease characteristics by dementia diagnosis, (2) time to
conﬁrmation of diagnosis from the initial visit, (3) resource
use during the diagnostic work-up period, (4) proportion
of the patients treated with cholinesterase inhibitors or
memantine at time of diagnosis conﬁrmation by dementia
diagnosis, (5) time to treatment initiation if not treated at
time of conﬁrmation, (6) time to treatment discontinuation
if treated, (7) time to conversion to the dementia phase
for patients with predementia, and (8) time to institutional
care. The study cohort for these analyses was based on 2,783
patientswhowereconﬁrmedwithadementia(n = 1,882)or
predementia (n = 901) diagnosis within two years since the
initialvisit.Themaximumtwo-yeartimetodiagnosisconﬁr-
mation was used to exclude those cases that may not actually
have any dementia. The study cohort was selected from more
than 19,000 subjects in the New England VA Healthcare
System between January 1, 2002 and December 31, 2009
and who had one of the following dementia diagnoses
Alzheimer disease (AD), senile and presenile of dementia
of the AD type, vascular dementia (VaD), frontotemporal
dementia(FTD),Lewybody dementia(LBD),mildcognitive
impairment (MCI), memory loss, and cognitive deﬁcits
of cerebrovascular disease (CD-CVD). Additional inclusion
criteria included patients at least 55 years of age at time
of ﬁrst dementia diagnosis, a 12-month baseline period in
the VA system free of any dementia diagnosis prior to the
ﬁrst dementia diagnosis, and no record of cholinesterase
inhibitors or memantine during the baseline period. Speciﬁc
types of dementia diagnosis were conﬁrmed if patients met
one of the following two criteria: (1) at least two identical
dementia ICD-9 diagnoses given by a recognized specialist,
separated by a period of at least 30 days, and (2) at least one
ICD-9 diagnosis of dementia accompanied by a recognized
dementia medication, including donepezil, rivastigmine,
galantamine, or memantine. Descriptive statistical analyses
and derivations of parametric equations to predict time to
events based on patient characteristics were performed.
Among the patients with a conﬁrmed diagnosis (n =
2,783), 68% of them were conﬁrmed with a dementia
diagnosis and 32% with a predementia diagnosis. For those
with a dementia diagnosis, 67% had a conﬁrmed diagnosis
of AD or mixed AD, 28% had a VaD, and the remaining
5% had other dementia diagnoses, such as LBD, FTD, and
mixed non-AD. For those diagnoses with predementia, 65%
were assumed to have prodromal AD, which was estimated
based on a chart review of a subset of these patients. The
mean age at initial diagnosis was about 78 years for patients
with predementia and 82 years for patients with dementia.
Comorbiditieswerehighlyprevalentamongthestudycohort
due to their advanced age, with about 20% with a CVD, 27%
with diabetes, 47% with coronary heart disease, 80% with
hypertension, and 5% on antipsychotics at baseline.
C. Cost Inputs
C.1. Diagnostic Work-Up. The costs of diagnostic work-up,
including a series of oﬃce visits to primary care physicians
and specialists, lab tests, and outpatient clinic visits, were
estimated based on the time taken to conﬁrm a diagnosis
from the initial oﬃce visit. Data for healthcare resource use
during the diagnostic work-up period were obtained forInternational Journal of Alzheimer’s Disease 15
each dementia diagnosis from the VA VISN 1 data and were
translated into costs by applying the unit costs from the
Centers for Medicare & Medicaid Services (CMS) [16–18].
The estimated costs of diagnostic work-up for each diagnosis
p e ry e a ra r es h o w ni nTable 4 of the main text.
C.2. Imaging and Biomarker Tests. The costs of brain
imaging and biomarker analyses, a one-time cost based
on the distribution of diagnostic algorithms assigned, were
estimated using the cost data from CMS hospital outpatient
fee schedule [16]( Table 4). The cost of ﬂorbetaben PET was
set at $2,300 per test in the base-case analysis, which was
suggested by the manufacturer of ﬂorbetaben.
C.3. Dementia Medication. Unit costs for dementia medica-
tions were based on the average wholesale price reported in
the Red Book [19]( Table 4). The daily costs for these drugs
were estimated based on their recommended dose and usage
from the licensed labels.
C.4. Medical and Nonmedical Care for Predementia and
Dementia. Costs of care were separated into costs of medical
and nonmedical care. For patients with AD, these costs
were obtained from a longitudinal study which followed
172 patients with probable AD for 4 years to examine the
eﬀects of patient dependence, measured by the Dependence
Scale, on the following: (1) medical care costs includ-
ing hospitalizations, outpatient treatments and procedures,
and assistive devices; (2) nonmedical care costs, including
overnight respite care, adult day care, and home healthcare;
(3) informal caregiving time, including time used for ADL
and for supervision [20]. As these outcomes of interest were
reported in relation to the Dependence Scale (range = 0–
15; higher scores indicate greater dependence), they were
mapped onto the MMSE scores using the data from the
same study to estimate the costs of medical and nonmedical
c a r e ,a sw e l la sc a r e g i v e rt i m e ,b yl e v e lo fs e v e r i t y ,d e ﬁ n e d
by MMSE scores. Table 4 shows the costs of medical and
nonmedical care and the amount of caregiver time by each
level of severity for patients with AD. As these costs were
measured in 2005 values, they were inﬂated to 2011 values
usingthemedicalservicescomponentoftheConsumerPrice
Index. The costs of care for patients with non-AD dementia
were also estimated based on patients’ levels of severity. The
annual costs of care for patients with VaD and other non-AD
were estimated by increasing 1.83 and 1.37 times the costs
forpatientswithAD,respectively.Theseratioswereobtained
from a study comparing the healthcare costs of community-
dwelling patients with VaD (n = 678) and other non-AD
dementia (n = 957) to patients with AD (n = 1,722) using
Medicare HMO data during 1999–2002 [21]. The amount of
caregiver time by level of severity for patients with non-AD
was assumed to be the same as that for patients with AD due
to lack of available data.
The cost of managing predementia in the US setting
was not identiﬁed from the literature search. Although some
studieswerefoundforothercountries[38,44],theywerenot
used in the analyses, as healthcare utilization patterns and
costs vary signiﬁcantly across countries. Thus, the average
cost based on the Dependence Scale of 0-1 obtained from the
study by Zhu and colleagues [20] was used to estimate the
cost of care and caregiver time for patients with predementia
(Table 4)[ 20].
D. Analyses
Model outcomes for the base-case analysis included percent
of patients misdiagnosed, time to diagnosis conﬁrmation,
number of predementia patients progressing to dementia,
life-years, time alive at each severity stage, percent of pa-
tients needing institutional care, time to institutional care,
caregiver time, costs, and QALYs for patients and caregivers.
Deterministic sensitivity analyses, including one-way, sub-
group, and scenario analyses, were performed to assess how
the model outcomes vary in relation to changes in model
parameters. Finally, in order to account for uncertainties
from multiple key parameters, probabilistic sensitivity anal-
yses were performed by simultaneously varying multiple
parameters under the following assumptions. First, for the
inputs which have no or little prior data to support, uniform
distributions were used as it is a more conservative assump-
tion. These parameters included the following: (1) sensitivity
(80% for the lower bound–96% for the upper bound)
and speciﬁcity (80–96%) of ﬂorbetaben PET, (2) percent
reduction (0–100%) in time to diagnosis conﬁrmation by
ﬂorbetaben PET, (3) percent reduction (0–100%) in risk
of conversion to dementia phase by treatment, and (4)
percent reduction (0–100%) in treatment discontinuation
by ﬂorbetaben PET. Second, for model inputs with prior
data to support, beta distributions were used for categorical
variables and normal distributions within 2 standard errors
of the mean as the upper and lower bounds were used for
continuous variables. For some of the parameters included
in the probabilistic sensitivity analyses, standard errors were
available from the parameter source data and thus used to
measure parameter uncertainties. Where a standard error
wasnotavailableforaselectedparameter,weused25%ofthe
mean as an assumed standard error. Parameters included in
the probabilistic sensitivity analyses and assumed to be beta
distributed were as follows: (1) percents of the predementia
and dementia patients treated at time of conﬁrmation under
usual diagnostic care, (2) ratios of cost of care for AD
versus VaD and non-AD, and (3) patient and caregiver
utilities for predementia patients. Parameters assumed to
be normally distributed included the following: (1) all
predictorcoeﬃcientsfortheparametricequations,including
time to diagnosis, time to treatment initiation, time to
treatment discontinuation, and time to institutional care; (2)
coeﬃcients for the treatment eﬀects on rates of change in
MMSE, NPI, ADL, and IADL over time; (3) hazard ratios
of death (with log transformation) compared to general
population for predementia, AD, and no-AD; (4) predictor
coeﬃcients for patient and caregiver utility equations for
dementia patients; (5) cost of dementia medications; (6)
costs of medical and nonmedical care for predementia and16 International Journal of Alzheimer’s Disease
dementia; (7) cost of institutional care; (8) caregiver burden
by severity level.
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